- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.03. | Galera Therapeutics GAAP EPS of -$0.10 | 4 | Seeking Alpha | ||
| 28.03. | Galera Therapeutics: Q4 Earnings Insights | 3 | Benzinga.com | ||
| 28.03. | Galera Therapeutics, Inc. - 10-K, Annual Report | 3 | SEC Filings | ||
| 28.03. | Galera Therapeutics: Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates | 129 | GlobeNewswire (Europe) | MALVERN, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have... ► Artikel lesen | |
| 27.03. | Galera Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 27.02. | Galera Therapeutics And 2 Other Stocks Under $3 Insiders Are Buying | 5 | Benzinga.com | ||
| 14.11.23 | Galera Therapeutics Inc reports results for the quarter ended in September - Earnings Summary | 5 | Reuters | ||
| 14.11.23 | Galera Therapeutics: Q3 Earnings Insights | 1 | Benzinga.com | ||
| 14.11.23 | Galera Therapeutics: Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates | 283 | GlobeNewswire (Europe) | FDA confirms need for new trial for avasopasem; GRECO trials with rucosopasem to be discontinued Company evaluating potential strategic options to optimize shareholder value MALVERN, Pa., Nov. 14... ► Artikel lesen | |
| 31.10.23 | Galera Therapeutics, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 31.10.23 | Galera Therapeutics: Galera Announces Receipt of Type A Meeting Minutes and Strategic Update | 338 | GlobeNewswire (Europe) | FDA confirms need for new trial for avasopasem for severe oral mucositis (SOM) GRECO-2 trial did not pass futility analysis; Company will discontinue both GRECO trials Company reviewing potential... ► Artikel lesen | |
| 14.08.23 | Galera Therapeutics: Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates | 286 | GlobeNewswire (Europe) | Company received Complete Response Letter from FDA for avasopasem and intends to request Type A meeting with FDA to discuss potential next steps Cash runway extended into Q2 2024 in connection with... ► Artikel lesen | |
| 09.08.23 | Galera Therapeutics: Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese | 592 | GlobeNewswire (Europe) | The Company remains committed to its goal of bringing avasopasem to patients and intends to meet with FDA as soon as possible to discuss potential next steps Galera will take actions to extend its... ► Artikel lesen | |
| 11.05.23 | Galera Therapeutics: Galera Reports First Quarter 2023 Financial Results and Recent Corporate Updates | 411 | GlobeNewswire (Europe) | Avasopasem NDA granted FDA priority review for radiotherapy-induced severe oral mucositis (SOM); PDUFA target date of August 9, 2023 Company raised $30 million in gross proceeds from registered direct... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,580 | -3,07 % | EQS-NVR: Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Epigenomics AG
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,850 | 0,00 % | Kaufen nach Abverkauf? Defence Therapeutics, Infineon Technologies, Super Micro Computer, TSMC Aktie | Die Marktteilnehmer waren nach den starken Kursrückgängen von Dow Jones und DAX sehr nervös. Schon panikartig wurden in der Nacht zu Freitag viele Aktien und damit auch Indizes abverkauft. Erst in den... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,772 | -7,99 % | Collaboration advancing new sourdough strain: Ginkgo Bioworks working with Italian baking ingredients company | ||
| BEAM THERAPEUTICS | 21,580 | -5,10 % | Expert Ratings For Beam Therapeutics | ||
| ONCOLYTICS BIOTECH | 1,030 | +4,04 % | Oncolytics Biotech® Inc.: Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting | SAN DIEGO and CALGARY, AB, April 25, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology,... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,815 | -1,57 % | Best biotech stocks to buy and hold in 2024: VKTX, SANA, RXRX | ||
| ARCTURUS THERAPEUTICS | 26,180 | -2,97 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| ASSERTIO | 0,785 | -9,27 % | Assertio Holdings, Inc. to Report First Quarter 2024 Financial Results on May 6, 2024 | ||
| SIGA TECHNOLOGIES | 8,540 | -1,39 % | SIGA Technologies - Positive signals abound | SIGA Technologies announced a strategic step in fortifying its distribution partner, Meridian, allowing greater control over planning and executing its international development efforts, a key growth... ► Artikel lesen | |
| MERRIMACK PHARMACEUTICALS | 14,730 | +0,14 % | Merrimack Pharmaceuticals, Inc. Reports Full Year 2023 Financial Results | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") today announced its full year 2023 financial results for the period ended December... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 7,630 | -5,10 % | How Vir found the one: CEO Marianne De Backer | ||
| VERVE THERAPEUTICS | 6,245 | -5,09 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 8,140 | -1,45 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy (Epinephrine Nasal Spray) | Response addresses all additional requests in FDA CRL, including positive data from a repeat dose PK/PD study of neffy under nasal allergen challenge (NAC) conditions, and updated testing that detected... ► Artikel lesen | |
| BIO-PATH | 2,670 | +6,80 % | Bio-Path files to sell 484K shares of common stock for holders | ||
| BIOMEA FUSION | 10,390 | -3,53 % | Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development... ► Artikel lesen |
GALERA THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,027 (+14,75 %) liegt der Kurs bei 0,208 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
